A comprehensive, multi-center US study involving 67 eligible patients examined the effectiveness of fecal microbiota, live-jslm (RBL), as a treatment option for recurrent Clostridioides difficile infection (rCDI). Results indicate a treatment success rate of 77.6% at an 8 week mark. Furthermore, a robust 87% of participants sustained remission at six months, reinforcing the safety and…